You have made a series of statements as facts which have not been reported by the company.IPIX PRs and Filings do not support your statements.
" Brilacidin is just not turning anyone on much anymore. By now we know why and it's the same reason the term sheet was dropped."
"The term sheet disappeared after the BTD deadline,"
"And he said no BP is interested in B"
All IPIX filings show the company is enthusiastic about Brilacidin. IPIX has not made a statement regarding the term sheet being rescinded.
"The Company signed a non-binding term sheet in August 2018 with a global pharmaceutical company for the licensing/rights to Brilacidin for treating oral mucositis and inflammatory bowel diseases. Initial payments, milestone payments and royalties are being negotiated in accordance with the non-binding term sheet. The pharmaceutical company is now engaged in further due diligence. Management can offer no assurances that the parties will enter into a binding definitive agreement."
"Management is pleased to report that, with the Holiday Season now over, discussions have resumed with potential pharmaceutical company partners, both overseas and domestic with a global presence. Licensing interest has been expressed in Brilacidin as a new drug candidate for Oral Mucositis and/or Inflammatory Bowel Disease."
In addition IPIX CEO, Leo Ehrlich, announced in the same PR above he acquired additional shares of IPIX.
We’re excited about 2019 and the opportunities surrounding our drug candidates. We see an industry where large pharmas are in need of replenishing their pipelines and, to that point, there has been plenty of interest in Brilacidin due to its unique qualities, broad applications and impressive body of clinical and pre-clinical data,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “We are active in advanced discussions with a variety of pharmaceuticals companies. Our goal remains to secure a partner for advanced clinical development of Brilacidin as a new therapeutic for Oral Mucositis and Inflammatory Bowel Disease. At that time, we intend to focus our resources on the next stages of development for Brilacidin, notably dermatologic indications, and Kevetrin as a novel anti-cancer agent to build upon the completed studies.”
The Company is actively engaged in business development and licensing initiatives with multiple specialty and global pharmaceutical companies across its entire pipeline of drugs. From time to time, the Company may be party to various indications of interest and term sheets and participate in preliminary discussions and negotiations regarding potential licensing or partnership arrangements. It remains the Company’s primary objective to complete licensing deals, territorial and/or global, to provide access to non-dilutive capital to advance clinical assets forward in the most expeditious and cost-effective manner. The Company can make no assurance that partnerships will occur but is committed toward executing on these potential alliance and partnership opportunities.
News 
Market Data 
Discover 
AI
